You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
|
|---|---|
| Published in |
JAMA Oncology, April 2016
|
| DOI | 10.1001/jamaoncol.2015.5009 |
| Pubmed ID | |
| Authors |
Lecia V. Sequist, Zofia Piotrowska, Matthew J. Niederst, Rebecca S. Heist, Subba Digumarthy, Alice T. Shaw, Jeffrey A. Engelman |
X Demographics
The data shown below were collected from the profiles of 28 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 11 | 39% |
| Spain | 6 | 21% |
| Belgium | 2 | 7% |
| Japan | 1 | 4% |
| Unknown | 8 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 43% |
| Practitioners (doctors, other healthcare professionals) | 8 | 29% |
| Scientists | 7 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 3% |
| Unknown | 33 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 26% |
| Other | 5 | 15% |
| Student > Master | 5 | 15% |
| Student > Bachelor | 4 | 12% |
| Student > Doctoral Student | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 4 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 44% |
| Biochemistry, Genetics and Molecular Biology | 4 | 12% |
| Agricultural and Biological Sciences | 4 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Social Sciences | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 6 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 July 2023.
All research outputs
#1,878,993
of 25,371,288 outputs
Outputs from JAMA Oncology
#2,040
of 3,308 outputs
Outputs of similar age
#30,769
of 314,718 outputs
Outputs of similar age from JAMA Oncology
#51
of 106 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 84.4. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,718 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.